A Randomized Study of an Over-the-Counter Magnolia Officinalis Supplement to Measure Its Effect on Immune Blood Markers in Adults with Psoriasis

What this Trial Is About

Researchers are investigating whether Viv, a consumer-grade dietary supplement made from Magnolia officinalis bark extract, affects immune activity markers in adults with psoriasis. This clinical trial compares Viv to a placebo to understand its impact on inflammation-related proteins. Participants have stable psoriasis confirmed by a dermatologist and may have related conditions like psoriatic arthritis if not requiring systemic treatments. Participants will be randomly assigned to take either Viv, containing 200 mg of Magnolia officinalis bark extract, or a placebo daily for three months. The study is triple-blinded, meaning neither the participants nor researchers know who receives which treatment. Participants will use the supplement at home and collect blood samples themselves at the start, after one month, and after three months using provided kits. During the study, participants will complete electronic questionnaires about their psoriasis symptoms and quality of life at the beginning, one month, and three months. Researchers will analyze blood samples to measure changes in inflammatory proteins and immune cells over time. The primary outcome is the change in plasma Beta defensin 2 levels after 12 weeks. The total study period for participants is three months, with ongoing safety and adherence monitored remotely.

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis